Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-06-15
1997-01-28
Peselev, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 23, A61K 3800
Patent
active
055978053
ABSTRACT:
Peritoneal dialysis solutions are specially formulated for use during and immediately after an episode of peritonitis. The solutions include one or more additives to minimize the injury and physiological effects that peritonitis can cause. One additive is a mixture of amino acids sufficient to maintain a positive nitrogen balance, at least one of the amino acids being present in a dipeptide form. Another additive is a compound that scavenges free radicals generated by peritoneal macrophages activated by the peritonitis. Another additive is chondroitin sulfate that changes the permeability of the peritoneal membrane during subsequent dialysis using solutions free of chondroitin sulfate. Another additive is the degradation products of hyaluronic acid to enhance the regeneration of the peritoneal mesothelium without fibrosis.
REFERENCES:
patent: 4339433 (1982-07-01), Kartinos et al.
patent: 4574085 (1986-03-01), Dolkart et al.
patent: 4761237 (1988-08-01), Alexander et al.
patent: 4828561 (1989-05-01), Woodruff
patent: 4863907 (1989-09-01), Sakurai et al.
patent: 4880629 (1989-11-01), Okamoto et al.
patent: 4886789 (1989-12-01), Milner
patent: 4906616 (1990-03-01), Gilchrist et al.
patent: 4959175 (1990-09-01), Yatzidis
patent: 4976683 (1990-12-01), Gauthier et al.
patent: 5011826 (1991-04-01), Steudle et al.
patent: 5039609 (1991-08-01), Klein
Morrison et al, Organic Chemistry, 3rd edition, (1979) pp. 1132-1143.
"Effects of Chondroitin Sulphate on Fluid and Solute Transport During Peritoneal Dialysis in Rats"; Breborowicz et al., Peritoneal Dialysis International, ol. 11, pp. 351-354; 1991.
"Cytotoxic Effects of Commercial Continuous Ambulatory Peritoneal Dialysis (CAPD) Fluids of Bacterial Exoproducts on Human Mesothelial Cells In Vitro"; Bronswijk et al., Peritoneal Dialysis Intl., vol. 9, pp. 197-202, 1969.
Abstracts 17, 18, 19 and 20, Peritoneal Dialysis International, vol. 10 (1990) published Feb. 8, 1990.
Abstracts 30-35, Peritoneal Dialysis International, vol. 11 (1991), published Feb. 6, 1991.
Breborowicz Andrzej
Oreopoulos Dimitrios G.
Barrett Robert M.
Baxter International Inc.
Borecki Thomas S.
Mattenson Charles R.
Peselev Elli
LandOfFree
Peritoneal dialysis solutions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peritoneal dialysis solutions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peritoneal dialysis solutions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-941548